These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24151282)

  • 1. Effects of commonly used medications on bone tissue mineralisation in SaOS-2 human bone cell line: an in vitro study.
    Salai M; Somjen D; Gigi R; Yakobson O; Katzburg S; Dolkart O
    Bone Joint J; 2013 Nov; 95-B(11):1575-80. PubMed ID: 24151282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.
    Lazzerini PE; Capperucci C; Spreafico A; Capecchi PL; Niccolini S; Ferrata P; Frediani B; Galeazzi M; Laghi-Pasini F
    Joint Bone Spine; 2013 Mar; 80(2):195-200. PubMed ID: 22999910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Citalopram and sertraline exposure compromises embryonic bone development.
    Fraher D; Hodge JM; Collier FM; McMillan JS; Kennedy RL; Ellis M; Nicholson GC; Walder K; Dodd S; Berk M; Pasco JA; Williams LJ; Gibert Y
    Mol Psychiatry; 2016 May; 21(5):656-64. PubMed ID: 26347317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct effects of rosuvastatin on pancreatic human beta cells.
    Bugliani M; Syed F; Masini M; Marselli L; Suleiman M; Novelli M; Filipponi F; Boggi U; Masiello P; De Tata V; Marchetti P
    Acta Diabetol; 2013 Dec; 50(6):983-5. PubMed ID: 23503985
    [No Abstract]   [Full Text] [Related]  

  • 5. Rosuvastatin promotes osteoblast differentiation and regulates SLCO1A1 transporter gene expression in MC3T3-E1 cells.
    Monjo M; Rubert M; Ellingsen JE; Lyngstadaas SP
    Cell Physiol Biochem; 2010; 26(4-5):647-56. PubMed ID: 21063102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological and clinical profile of rosuvastatin calcium (Crestor)].
    Ohfuji K; Yano S; Yamaguchi M; Smith G; Hirata M; Shimada H; Izuishi K; Shinagawa J; Matsunaga K
    Nihon Yakurigaku Zasshi; 2005 Sep; 126(3):213-9. PubMed ID: 16272766
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?
    Yavuz B; Ertugrul DT; Cil H; Ata N; Akin KO; Yalcin AA; Kucukazman M; Dal K; Hokkaomeroglu MS; Yavuz BB; Tutal E
    Cardiovasc Drugs Ther; 2009 Aug; 23(4):295-9. PubMed ID: 19543962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.
    Capra V; Rovati GE
    Pulm Pharmacol Ther; 2014 Feb; 27(1):10-6. PubMed ID: 23806820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Omeprazole on the Pharmacokinetics of Rosuvastatin in Healthy Male Volunteers.
    Shah Y; Iqbal Z; Ahmad L; Khuda F; Khan A; Khan A; Khan MI; Ismail
    Am J Ther; 2016; 23(6):e1514-e1523. PubMed ID: 25719441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.
    Habibi J; Whaley-Connell A; Qazi MA; Hayden MR; Cooper SA; Tramontano A; Thyfault J; Stump C; Ferrario C; Muniyappa R; Sowers JR
    Endocrinology; 2007 May; 148(5):2181-8. PubMed ID: 17317778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D.
    Ertugrul DT; Yavuz B; Cil H; Ata N; Akin KO; Kucukazman M; Yalcin AA; Dal K; Yavuz BB; Tutal E
    Cardiovasc Ther; 2011 Apr; 29(2):146-52. PubMed ID: 20370794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model.
    Crestini A; Piscopo P; Iazeolla M; Albani D; Rivabene R; Forloni G; Confaloni A
    J Mol Neurosci; 2011 Mar; 43(3):461-9. PubMed ID: 20981578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the nitric oxide on rosuvastatin-induced relaxation of the calf cardiac vein during cooling.
    Guresir MS; Nurullahoglu KE
    Bratisl Lek Listy; 2014; 115(12):753-6. PubMed ID: 25520222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of statins on glucose metabolism--a matter of debate.
    Anagnostis P; Athyros VG; Karagiannis A; Mikhailidis DP
    Am J Cardiol; 2011 Jun; 107(12):1866. PubMed ID: 21640222
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells.
    Chen CH; Cheng CY; Chen YC; Sue YM; Hsu YH; Tsai WL; Chen TH
    Eur J Pharmacol; 2013 Jan; 700(1-3):65-73. PubMed ID: 23276663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance in patients undergoing peritoneal dialysis: can we improve it? : editorial to: "the effect of HM-CoA reductase inhibitor on insulin resistance in patients undergoing peritoneal dialysis" by Fa Mee Doh et al.
    King-Morris K; Ikizler TA
    Cardiovasc Drugs Ther; 2012 Dec; 26(6):441-3. PubMed ID: 23161070
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin.
    Holdgate GA; Ward WH; McTaggart F
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):528-31. PubMed ID: 12773150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin.
    El Sharkawi FZ; El Shemy HA; Khaled HM
    Asian Pac J Cancer Prev; 2014; 15(1):199-203. PubMed ID: 24528027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
    Stalker TJ; Lefer AM; Scalia R
    Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.